Sanofi–GSK COVID-19 vaccine: Difference between revisions
Content deleted Content added
Come on. |
|||
| (18 intermediate revisions by 13 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description| |
{{Short description|Protein subunit vaccine against COVID-19}} |
||
{{cs1 config|name-list-style=vanc}} |
|||
<!-- recommended structure: see WP:MEDORDER and WP:DRUGLIKE --> |
<!-- recommended structure: see WP:MEDORDER and WP:DRUGLIKE --> |
||
{{Use dmy dates|date=August 2021}} |
{{Use dmy dates|date=August 2021}} |
||
| Line 31: | Line 32: | ||
| ATCvet = |
| ATCvet = |
||
| ATC_prefix = J07 |
| ATC_prefix = J07 |
||
| ATC_suffix = |
| ATC_suffix = BN04 |
||
| ATC_supplemental = |
| ATC_supplemental = |
||
| Line 50: | Line 51: | ||
| legal_US_comment = |
| legal_US_comment = |
||
| legal_EU = Marketing authorization granted |
| legal_EU = Marketing authorization granted |
||
| legal_EU_comment = <ref name="VidPrevtyn Beta EPAR">{{cite web | title=VidPrevtyn Beta | website=[[European Medicines Agency]] (EMA) | date=4 November 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta | access-date=12 November 2022}} Text was copied from this source which is |
| legal_EU_comment = <ref name="VidPrevtyn Beta EPAR">{{cite web | title=VidPrevtyn Beta | website=[[European Medicines Agency]] (EMA) | date=4 November 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta | access-date=12 November 2022}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref name="EMA PR 20221110">{{cite press release | title=EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine | website=[[European Medicines Agency]] (EMA) | date=10 November 2022 | url=https://www.ema.europa.eu/en/news/ema-recommends-approval-vidprevtyn-beta-covid-19-booster-vaccine | access-date=12 November 2022}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> |
||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
||
| legal_UN_comment = |
| legal_UN_comment = |
||
| Line 67: | Line 68: | ||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number_Ref = <ref>{{cite web|url=https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-and-therapeutics.pdf|title=Patent Landscape Report COVID-19-related vaccines and therapeutics}}</ref> |
|||
| CAS_number_Ref = |
|||
| CAS_number = |
| CAS_number = 2696235-99-9 |
||
| CAS_supplemental = |
|||
| PubChem = |
| PubChem = |
||
| IUPHAR_ligand = |
| IUPHAR_ligand = |
||
| Line 113: | Line 113: | ||
{{COVID-19 pandemic sidebar}} |
{{COVID-19 pandemic sidebar}} |
||
The '''Sanofi–GSK COVID-19 vaccine''' sold under the brand name '''VidPrevtyn Beta''', is a [[COVID-19 vaccine]] developed by [[Sanofi Pasteur]] and [[GlaxoSmithKline|GSK]].<ref>{{cite web |title=Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older. |url=https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475 |website=pactr.samrc.ac.za |publisher=Pan African Clinical Trials Registry |access-date=24 March 2021 }}</ref><ref>{{#invoke:Cite web| |
The '''Sanofi–GSK COVID-19 vaccine''', sold under the brand name '''VidPrevtyn Beta''', is a [[COVID-19 vaccine]] developed by [[Sanofi Pasteur]] and [[GlaxoSmithKline|GSK]].<ref>{{cite web |title=Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older. |url=https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475 |website=pactr.samrc.ac.za |publisher=Pan African Clinical Trials Registry |access-date=24 March 2021 }}</ref><ref>{{#invoke:Cite web||title=Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008) |url=https://clinicaltrials.gov/ct2/show/study/NCT04904549 |website=ClinicalTrials.gov |access-date=28 May 2021 }}</ref> |
||
The Sanofi–GSK COVID{{nbhyph}}19 vaccine was approved for medical use in the European Union in November 2022.<ref name="VidPrevtyn Beta EPAR" /><ref name="EMA PR 20221110" /><ref>{{cite press release | title=Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission | website=GSK | date=10 November 2022 | url=https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-s-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-ec/ | access-date=12 November 2022}}</ref><ref>{{cite press release | title=Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission | website=Sanofi | date=10 November 2022 | url=https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-10-15-36-50-2553486 | access-date=12 November 2022}}</ref> |
The Sanofi–GSK COVID{{nbhyph}}19 vaccine was approved for medical use in the European Union in November 2022.<ref name="VidPrevtyn Beta EPAR" /><ref name="EMA PR 20221110" /><ref>{{cite press release | title=Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission | website=GSK | date=10 November 2022 | url=https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-s-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-ec/ | access-date=12 November 2022}}</ref><ref>{{cite press release | title=Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission | website=Sanofi | date=10 November 2022 | url=https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-10-15-36-50-2553486 | access-date=12 November 2022}}</ref> |
||
| Line 131: | Line 131: | ||
In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States.<ref>{{Cite journal|id=NCT04762680|title=Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)|url=https://www.clinicaltrials.gov/ct2/show/NCT04762680|website=ClinicalTrials.gov|date=21 February 2021}}</ref> |
In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States.<ref>{{Cite journal|id=NCT04762680|title=Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)|url=https://www.clinicaltrials.gov/ct2/show/NCT04762680|website=ClinicalTrials.gov|date=21 February 2021}}</ref> |
||
On 27 May 2021, the vaccine began a Phase{{Nbsp|1}}III trial involving 35,000 participants,<ref>{{Cite news| |
On 27 May 2021, the vaccine began a Phase{{Nbsp|1}}III trial involving 35,000 participants,<ref>{{Cite news| vauthors = Armitage J |date=27 May 2021|title=GlaxoSmithKline shareholders "relieved" as Elliott rules out aggressive demands|work=[[London Evening Standard]]|url=https://www.standard.co.uk/business/glaxosmithkline-shareholders-relieved-as-elliott-rules-out-aggressive-demands-b937644.html}}</ref><ref>{{cite press release | title=Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate | website=Sanofi | date=27 May 2021 | url=https://www.sanofi.com/en/media-room/press-releases/2021/2021-05-27-07-30-00-2236989 | access-date=22 July 2021}}</ref><ref>{{cite web | title=Phase 3 Clinical Trial for COVID-19 Recombinant Protein Vaccine Candidate | website=Sanofi | url=https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate | access-date=22 July 2021 | archive-date=23 July 2021 | archive-url=https://web.archive.org/web/20210723064010/https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate | url-status=dead }}</ref> which increased to 37,430 participants with trials in Colombia, Dominican Republic, Ghana, Honduras, India, Japan, Kenya, Mexico,<ref>{{#invoke:Cite web ||title=Tarjeta del participante del estudio VAT00008: ejemplo central para adaptación a nivel de país |url=http://interoperabilidad.incmnsz.mx:8080/inv2014/seguimiento_protocolo/protocolos/3725//EN-ES_Subject%20Participation%20Card_Mx_VAT00008_Dr%20Sifuentes%20(1).pdf |trans-title=VAT00008 Study Participant Card: Central Example for Country-Level Adaptation |date=15 April 2021 |publisher=[[Salvador Zubirán National Institute of Health Sciences and Nutrition]] |website=incmnsz.mx}}</ref> Nigeria, Pakistan, Sri Lanka, Uganda, and the United States.<ref>{{#invoke:Cite web||title=Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older |url=http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=56682&EncHid=&userName=covid-19%20vaccine |website=ctri.nic.in |publisher=Clinical Trials Registry India |access-date=3 August 2021 |id=CTRI/2021/06/034442}}</ref> |
||
In September 2021, Sanofi-GSK started a booster trial in the United Kingdom. In this study, they will enroll up to 3,145 volunteers who have previously completed a COVID-19 a full vaccine course between 4 and 10 months previously. The purpose of this study is to determine if the investigational COVID-19 vaccines are safe and can stimulate and broaden the immune response against the different COVID-19 variants that cause COVID-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized COVID-19 vaccine.<ref>{{cite web|title=Covid-19 Booster Vaccine Clinical Study|url=https://www.sanofistudies.com/covidbooster#eligibility|website=Sanofi|date=22 October 2021|access-date=22 October 2021 |url-status=dead |archive-url=https://web.archive.org/web/20211030212712/https://www.sanofistudies.com/covidbooster |archive-date=30 October 2021}}</ref> |
In September 2021, Sanofi-GSK started a booster trial in the United Kingdom. In this study, they will enroll up to 3,145 volunteers who have previously completed a COVID-19 a full vaccine course between 4 and 10 months previously. The purpose of this study is to determine if the investigational COVID-19 vaccines are safe and can stimulate and broaden the immune response against the different COVID-19 variants that cause COVID-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized COVID-19 vaccine.<ref>{{cite web|title=Covid-19 Booster Vaccine Clinical Study|url=https://www.sanofistudies.com/covidbooster#eligibility|website=Sanofi|date=22 October 2021|access-date=22 October 2021 |url-status=dead |archive-url=https://web.archive.org/web/20211030212712/https://www.sanofistudies.com/covidbooster |archive-date=30 October 2021}}</ref> |
||
=== Non-clinical studies === |
=== Non-clinical studies === |
||
During its development, the vaccine was tested in several non-clinical models including mice, hamsters, rabbits and non-human primates.<ref>{{cite journal | vauthors = Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, Gagne M, Johnston TS, Tucker C, Davis RL, Flach B, O'Connell S, Andrew SF, Lamb E, Flebbe DR, Nurmukhambetova ST, Donaldson MM, Todd JM, Zhu AL, Atyeo C, Fischinger S, Gorman MJ, Shin S, Edara VV, Floyd K, Lai L, Boyoglu-Barnum S, Van De Wetering R, Tylor A, McCarthy E, Lecouturier V, Ruiz S, Berry C, Tibbitts T, Andersen H, Cook A, Dodson A, Pessaint L, Van Ry A, Koutsoukos M, Gutzeit C, Teng IT, Zhou T, Li D, Haynes BF, Kwong PD, McDermott A, Lewis MG, Fu TM, Chicz R, van der Most R, Corbett KS, Suthar MS, Alter G, Roederer M, Sullivan NJ, Douek DC, Graham BS, Casimiro D, Seder RA | display-authors = 6 | title = Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates | journal = Science Translational Medicine | volume = 13 | issue = 607 | date = August 2021 | pmid = 34315825 | pmc = 9266840 | doi = 10.1126/scitranslmed.abi4547 }}</ref><ref>{{cite journal | vauthors = Pavot V, Berry C, Kishko M, Anosova NG, Huang D, Tibbitts T, Raillard A, Gautheron S, Gutzeit C, Koutsoukos M, Chicz RM, Lecouturier V | display-authors = 6 | title = Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates | journal = Nature Communications | volume = 13 | issue = 1 | pages = 1699 | date = March 2022 | pmid = 35361754 | pmc = 8971430 | doi = 10.1038/s41467-022-29219-2 | bibcode = 2022NatCo..13.1699P }}</ref><ref>{{cite journal | vauthors = Pavot V, Berry C, Kishko M, Anosova NG, Li L, Tibbitts T, Huang D, Raillard A, Gautheron S, Gutzeit C, Koutsoukos M, Chicz RM, Lecouturier V | display-authors = 6 | title = Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates | journal = Nature Communications | volume = 14 | issue = 1 | pages = 1309 | date = March 2023 | pmid = 36894558 | pmc = 9998256 | doi = 10.1038/s41467-023-36908-z | bibcode = 2023NatCo..14.1309P }}</ref><ref>{{cite journal | vauthors = Berry C, Pavot V, Anosova NG, Kishko M, Li L, Tibbitts T, Raillard A, Gautheron S, Cummings S, Bangari DS, Kar S, Atyeo C, Deng Y, Alter G, Gutzeit C, Koutsoukos M, Chicz RM, Lecouturier V | display-authors = 6 | title = Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters | journal = Communications Medicine | volume = 3 | issue = 1 | pages = 75 | date = May 2023 | pmid = 37237062 | pmc = 10212738 | doi = 10.1038/s43856-023-00302-z }}</ref> |
|||
During its development, the vaccine was tested in several non-clinical models including mice, hamsters, rabbits and non-human primates.<ref>Francica et al. https://www.science.org/doi/full/10.1126/scitranslmed.abi4547?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org</ref><ref>Pavot et al. https://www.nature.com/articles/s41467-022-29219-2</ref><ref>Pavot et al. https://www.nature.com/articles/s41467-023-36908-z</ref> |
|||
== Society and culture == |
== Society and culture == |
||
=== Legal status === |
=== Legal status === |
||
In July 2021, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] (EMA) started a rolling review of Vidprevtyn, a COVID-19 vaccine developed by Sanofi Pasteur.<ref name="EMA rolling review">{{cite press release | title=EMA starts rolling review of COVID-19 vaccine Vidprevtyn | website=[[European Medicines Agency]] (EMA) | date=20 July 2021 | url=https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vidprevtyn | access-date=22 July 2021}} Text was copied from this source which is |
In July 2021, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] (EMA) started a rolling review of Vidprevtyn, a COVID-19 vaccine developed by Sanofi Pasteur.<ref name="EMA rolling review">{{cite press release | title=EMA starts rolling review of COVID-19 vaccine Vidprevtyn | website=[[European Medicines Agency]] (EMA) | date=20 July 2021 | url=https://www.ema.europa.eu/en/news/ema-starts-rolling-review-covid-19-vaccine-vidprevtyn | access-date=22 July 2021}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.<ref name="EMA rolling review" /> Vidprevtyn Beta was approved for medical use in the European Union in November 2022.<ref name="VidPrevtyn Beta EPAR" /><ref name="EMA PR 20221110" /><ref>{{cite web | title=Vidprevtyn Beta Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1580.htm | access-date=3 March 2023}}</ref> |
||
=== Economics === |
=== Economics === |
||
In July 2020, the UK government signed up for 60 million doses of a [[COVID-19 vaccine]] developed by [[GlaxoSmithKline|GSK]] and [[Sanofi]]. It uses a [[recombinant DNA|recombinant protein]]-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.<ref>{{Cite web|url=https://www.bbc.com/news/business-53577637|title=Coronavirus vaccine: UK signs deal with GSK and Sanofi|date=29 July 2020| work = BBC News }}</ref> The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.<ref name = "CNBC_2001">{{cite web | vauthors = Lovelace Jr B |url=https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html|title=U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine|date=31 July 2020|publisher=CNBC}}</ref> |
In July 2020, the UK government signed up for 60 million doses of a [[COVID-19 vaccine]] developed by [[GlaxoSmithKline|GSK]] and [[Sanofi]]. It uses a [[recombinant DNA|recombinant protein]]-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.<ref>{{Cite web|url=https://www.bbc.com/news/business-53577637|title=Coronavirus vaccine: UK signs deal with GSK and Sanofi|date=29 July 2020| work = BBC News }}</ref> The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.<ref name = "CNBC_2001">{{cite web | vauthors = Lovelace Jr B |url=https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html|title=U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine|date=31 July 2020|publisher=CNBC}}</ref> |
||
=== Marketing === |
|||
In March 2024, at the request of Sanofi Pasteur, the European Commission withdrew the marketing authorization for VidPrevtyn. Sanofi Pasteur said the decision for the discontinuation was due to commercial reasons.<ref>{{Cite web |title=VidPrevtyn Beta |url=https://www.ema.europa.eu/en/documents/public-statement/public-statement-vidprevtyn-beta-withdrawal-marketing-authorisation-european-union_en.pdf |website=[[European Medicines Agency]]}}</ref> |
|||
== See also == |
|||
* [[Corbevax]] |
|||
== References == |
== References == |
||
| Line 158: | Line 165: | ||
{{DEFAULTSORT:Sanofi-Gsk Covid-19 Vaccine}} |
{{DEFAULTSORT:Sanofi-Gsk Covid-19 Vaccine}} |
||
[[Category: |
[[Category:Drugs developed by GSK plc]] |
||
[[Category:Clinical trials sponsored by GSK plc]] |
|||
[[Category:American COVID-19 vaccines]] |
[[Category:American COVID-19 vaccines]] |
||
[[Category:Products introduced in 2020]] |
[[Category:Products introduced in 2020]] |
||
Latest revision as of 03:58, 29 November 2024
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Vidprevtyn Beta |
| Other names | VAT00002, VAT00008 |
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
The Sanofi–GSK COVID-19 vaccine, sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.[4][5]
The Sanofi–GSK COVID‑19 vaccine was approved for medical use in the European Union in November 2022.[1][2][6][7]
Medical uses
[edit]The Sanofi–GSK COVID‑19 vaccine is used as a booster for active immunisation against SARS‑CoV‑2 virus in order to prevent COVID‑19.[1][2]
Pharmacology
[edit]The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine.[8][9]
History
[edit]The Sanofi–GSK COVID‑19 vaccine is under development by the French pharmaceutical company Sanofi and the British-American pharmaceutical company GlaxoSmithKline.[10] Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.[11]
Clinical trials
[edit]In September 2020, Sanofi-GSK started for phase I trials with 440 participants in the United States.[12]
In February 2021, Sanofi-GSK started for phase II trials with 722 participants in the United States.[13]
On 27 May 2021, the vaccine began a Phase III trial involving 35,000 participants,[14][15][16] which increased to 37,430 participants with trials in Colombia, Dominican Republic, Ghana, Honduras, India, Japan, Kenya, Mexico,[17] Nigeria, Pakistan, Sri Lanka, Uganda, and the United States.[18]
In September 2021, Sanofi-GSK started a booster trial in the United Kingdom. In this study, they will enroll up to 3,145 volunteers who have previously completed a COVID-19 a full vaccine course between 4 and 10 months previously. The purpose of this study is to determine if the investigational COVID-19 vaccines are safe and can stimulate and broaden the immune response against the different COVID-19 variants that cause COVID-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized COVID-19 vaccine.[19]
Non-clinical studies
[edit]During its development, the vaccine was tested in several non-clinical models including mice, hamsters, rabbits and non-human primates.[20][21][22][23]
Society and culture
[edit]Legal status
[edit]In July 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of Vidprevtyn, a COVID-19 vaccine developed by Sanofi Pasteur.[24] The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.[24] Vidprevtyn Beta was approved for medical use in the European Union in November 2022.[1][2][25]
Economics
[edit]In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.[26] The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.[27]
Marketing
[edit]In March 2024, at the request of Sanofi Pasteur, the European Commission withdrew the marketing authorization for VidPrevtyn. Sanofi Pasteur said the decision for the discontinuation was due to commercial reasons.[28]
See also
[edit]References
[edit]- ^ a b c d "VidPrevtyn Beta". European Medicines Agency (EMA). 4 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d "EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine". European Medicines Agency (EMA) (Press release). 10 November 2022. Retrieved 12 November 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.
- ^ "Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)". ClinicalTrials.gov. Retrieved 28 May 2021.
- ^ "Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission". GSK (Press release). 10 November 2022. Retrieved 12 November 2022.
- ^ "Press Release: Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission". Sanofi (Press release). 10 November 2022. Retrieved 12 November 2022.
- ^ "Sanofi, GSK announce positive results for Covid-19 vaccine candidate". STAT. 17 May 2021. Retrieved 18 May 2021.
- ^ "The Adjuvanted Recombinant Protein-based Vaccine Candidate". Sanofi. Archived from the original on 18 May 2021. Retrieved 18 May 2021.
- ^ "Coronavirus vaccine trial begun by drug firms GSK and Sanofi". BBC News Online. 3 September 2020. Retrieved 20 April 2021.
- ^ Taylor NP (11 December 2020). "Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine". Fierce Biotech. Retrieved 25 January 2021.
- ^ "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". ClinicalTrials.gov. 3 September 2020. NCT04537208.
- ^ "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". ClinicalTrials.gov. 21 February 2021. NCT04762680.
- ^ Armitage J (27 May 2021). "GlaxoSmithKline shareholders "relieved" as Elliott rules out aggressive demands". London Evening Standard.
- ^ "Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate". Sanofi (Press release). 27 May 2021. Retrieved 22 July 2021.
- ^ "Phase 3 Clinical Trial for COVID-19 Recombinant Protein Vaccine Candidate". Sanofi. Archived from the original on 23 July 2021. Retrieved 22 July 2021.
- ^ "Tarjeta del participante del estudio VAT00008: ejemplo central para adaptación a nivel de país" [VAT00008 Study Participant Card: Central Example for Country-Level Adaptation] (PDF). incmnsz.mx. Salvador Zubirán National Institute of Health Sciences and Nutrition. 15 April 2021.
- ^ "Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older". ctri.nic.in. Clinical Trials Registry India. CTRI/2021/06/034442. Retrieved 3 August 2021.
- ^ "Covid-19 Booster Vaccine Clinical Study". Sanofi. 22 October 2021. Archived from the original on 30 October 2021. Retrieved 22 October 2021.
- ^ Francica JR, Flynn BJ, Foulds KE, Noe AT, Werner AP, Moore IN, et al. (August 2021). "Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates". Science Translational Medicine. 13 (607). doi:10.1126/scitranslmed.abi4547. PMC 9266840. PMID 34315825.
- ^ Pavot V, Berry C, Kishko M, Anosova NG, Huang D, Tibbitts T, et al. (March 2022). "Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates". Nature Communications. 13 (1): 1699. Bibcode:2022NatCo..13.1699P. doi:10.1038/s41467-022-29219-2. PMC 8971430. PMID 35361754.
- ^ Pavot V, Berry C, Kishko M, Anosova NG, Li L, Tibbitts T, et al. (March 2023). "Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates". Nature Communications. 14 (1): 1309. Bibcode:2023NatCo..14.1309P. doi:10.1038/s41467-023-36908-z. PMC 9998256. PMID 36894558.
- ^ Berry C, Pavot V, Anosova NG, Kishko M, Li L, Tibbitts T, et al. (May 2023). "Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters". Communications Medicine. 3 (1): 75. doi:10.1038/s43856-023-00302-z. PMC 10212738. PMID 37237062.
- ^ a b "EMA starts rolling review of COVID-19 vaccine Vidprevtyn". European Medicines Agency (EMA) (Press release). 20 July 2021. Retrieved 22 July 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Vidprevtyn Beta Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ "Coronavirus vaccine: UK signs deal with GSK and Sanofi". BBC News. 29 July 2020.
- ^ Lovelace Jr B (31 July 2020). "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.
- ^ "VidPrevtyn Beta" (PDF). European Medicines Agency.
External links
[edit]
Scholia has a profile for Sanofi–GSK COVID-19 vaccine (Q106265257).
